[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:malignant-neoplasm-of-cardio-esophageal-junction-of-stomach":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":145,"states":150},"Malignant neoplasm of cardio-esophageal junction of stomach",22,18,[8,16,22,28,34,40,47,53,59,65,71,78,84,90,96,102,108,114,120,127,133,139],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07419841","A Phase 1 Study of the Safety and Tolerability of CTX-10726",[12],"Phase 1","RECRUITING","2026-08-26T02:18:55.570428Z","2026-07-05T05:32:16.684256Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03943004","Trial of DFP-14927 in Advanced Solid Tumors",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:29.398880Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT07277413","A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors",[12],"2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.679197Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06242470","A Study of MGC026 in Participants With Advanced Solid Tumors",[12],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:29.659697Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT06475937","A Study of DM001 in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.495832Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":45,"content_modified":46},"NCT06239194","Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors",[44],"Phase 1\u002FPhase 2","2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.493268Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06596694","Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)",[44],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:29.224419Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06065371","Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:29.211761Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT05274048","Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients",[12],"2026-08-26T02:16:33.772093Z","2026-05-05T02:43:28.987899Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":69,"content_modified":70},"NCT05267626","Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",[44],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:28.878293Z",{"nct_id":72,"title":73,"phases":74,"status":13,"updated_at":76,"content_modified":77},"NCT06695845","A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",[75],"Phase 2","2026-08-26T02:19:31.671303Z","2026-05-05T02:43:28.744064Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07335497","CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors",[44],"2026-08-26T02:15:59.318403Z","2026-05-05T02:43:27.638553Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06515990","A Study of DM005 in Patients With Advanced Solid Tumors",[12],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:26.960845Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06253871","A Phase 1\u002F1b Study of IAM1363 in HER2 Cancers",[12],"2026-08-26T02:18:31.944757Z","2026-05-05T02:35:31.700916Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT05941507","A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors",[44],"2026-08-26T02:17:01.714035Z","2026-04-29T02:57:57.104368Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT07318051","Sample Collection for Ongoing Research and Product Evaluation Study",[],"2026-08-26T02:15:33.331531Z","2026-05-13T02:55:06.687247Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06497569","Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer",[],"2026-08-26T02:18:47.742071Z","2026-05-05T02:43:26.906563Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06263088","EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.",[],"2026-08-26T02:19:04.543908Z","2026-05-05T02:43:27.634026Z",{"nct_id":121,"title":122,"phases":123,"status":124,"updated_at":125,"content_modified":126},"NCT06109467","Neratinib In Combination With Chemotherapy\u002FTrastuzumab\u002FPembrolizumab In HER2 Gastroesophageal Cancer",[75],"ACTIVE_NOT_RECRUITING","2026-08-03T02:11:04.414058Z","2026-05-05T02:43:28.964978Z",{"nct_id":128,"title":129,"phases":130,"status":124,"updated_at":131,"content_modified":132},"NCT04069273","Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma",[75],"2026-08-03T03:20:00.985008Z","2026-05-05T02:43:27.338792Z",{"nct_id":134,"title":135,"phases":136,"status":124,"updated_at":137,"content_modified":138},"NCT06257264","A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors",[12],"2026-08-03T03:31:44.965184Z","2026-05-05T02:43:29.667674Z",{"nct_id":140,"title":141,"phases":142,"status":124,"updated_at":143,"content_modified":144},"NCT06188702","S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP",[44],"2026-08-03T03:02:32.170340Z","2026-05-05T02:43:28.020362Z",[146],{"biomarker":147,"count":148,"slug":149},"ERBB2 Gene",3,"erbb2-gene",[151,155,159,163,167,171,174,178,181,184,187,191,194,197,200,203],{"state":152,"count":153,"slug":154},"Texas",15,"texas",{"state":156,"count":157,"slug":158},"Florida",11,"florida",{"state":160,"count":161,"slug":162},"Tennessee",10,"tennessee",{"state":164,"count":165,"slug":166},"California",9,"california",{"state":168,"count":169,"slug":170},"Michigan",8,"michigan",{"state":172,"count":169,"slug":173},"New York","new-york",{"state":175,"count":176,"slug":177},"Colorado",5,"colorado",{"state":179,"count":176,"slug":180},"Pennsylvania","pennsylvania",{"state":182,"count":176,"slug":183},"Utah","utah",{"state":185,"count":176,"slug":186},"Virginia","virginia",{"state":188,"count":189,"slug":190},"New Jersey",4,"new-jersey",{"state":192,"count":189,"slug":193},"Ohio","ohio",{"state":195,"count":148,"slug":196},"Illinois","illinois",{"state":198,"count":148,"slug":199},"Massachusetts","massachusetts",{"state":201,"count":148,"slug":202},"Missouri","missouri",{"state":204,"count":148,"slug":205},"North Carolina","north-carolina"]